These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 421176)

  • 1. Cellular immunity in Hodgkin's disease.
    Advani SH; D'Silva H; Gothoskar BP; Dinshaw KA; Nair CN; Gopalkrishna R; Talwalkar GV; Desai PB
    Cancer; 1979 Feb; 43(2):492-9. PubMed ID: 421176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restoration of cellular immune response by levamisole in patients with Hodgkin's disease.
    Levo Y; Rotter V; Ramot B
    Biomedicine; 1975 Jun; 23(6):198-200. PubMed ID: 1082352
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Disorders of cellular immunity in Hodgkin's disease].
    Burchardt K
    Pol Arch Med Wewn; 1981 Aug; 66(2):133-41. PubMed ID: 7033936
    [No Abstract]   [Full Text] [Related]  

  • 4. Zinc and anergy in pediatric Hodgkin's disease in Turkey.
    Cavdar AO; Babacan E; Gözdaşoğlu S; Erten J; Cin S; Arcasoy A; Ertem U
    Cancer; 1987 Jan; 59(2):305-9. PubMed ID: 3802017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Persisting deficiency of cell mediated immunity in Hodgkin's disease in complete remission (author's transl)].
    Lang JM; Bigel P; Giron C; Faradji A; Oberling F; Mayer S
    Nouv Presse Med; 1979 Nov; 8(44):3629-32. PubMed ID: 316521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of radiochemotherapy and splenectomy on cellular immunity in long-term survivors of Hodgkin's disease and non-Hodgkin's lymphoma.
    Steele R; Han T
    Cancer; 1978 Jul; 42(1):133-9. PubMed ID: 667791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of multiple in vivo and in vitro parameters in untreated patients with Hodgkin's disease.
    Case DC; Hansen JA; Corrales E; Young CW; Dupont B; Pinsky CM; Good RA
    Cancer; 1976 Oct; 38(4):1807-15. PubMed ID: 1086708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Possible nonspecific immunopotentiation by 2,4-dinitrochlorobenzene sensitization in patients with Hodgkin's disease.
    Rubinstein A; Ghossein NA; Melamed J; Bosworth JL; Murphy RA
    Oncology; 1979; 36(1):23-6. PubMed ID: 313034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impaired lymphocyte transformation in Hodgkin's disease. Evidence for depletion of circulating t-lymphocytes.
    Matchett KM; Huang AT; Kremer WB
    J Clin Invest; 1973 Aug; 52(8):1908-17. PubMed ID: 4541673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunological monitoring in lung cancer: use of the leukocyte migration inhibition assay.
    Abai AM; Fekete B
    Haematologia (Budap); 1982; 15(1):111-25. PubMed ID: 6749608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parallel tubular structures in lymphocytes. II. Correlation with cellular immunity and cytomegalovirus and Epstein-Barr virus antibodies in Hodgkin's disease.
    Halie MR; Langenhuysen MM; de Gast GC; Nieweg HO
    Acta Haematol; 1975; 54(2):82-8. PubMed ID: 169660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological monitoring during chemotherapy for advanced Hodgkin's disease.
    Alexopoulos CG; Wiltshaw E
    Cancer; 1978 Dec; 42(6):2631-40. PubMed ID: 310334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cellular immunity in patients with Hodgkin's disease: modification induced by incubating lymphocytes with fetal calf serum and Hodgkin's serum].
    Rambotti P; Velardi A; Spinozzi F; Falini B; Martelli MF
    Boll Ist Sieroter Milan; 1979 Mar; 58(1):90-9. PubMed ID: 552840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in vivo effect of thymic factor (thymostimulin) administration in Hodgkin's disease patients. Correlation of skin reactivity and leukocyte migration-inhibition factor in the sera of anergic subjects.
    Velardi A; Rambotti P; Cernetti C; Spinozzi F; Bertotto A; Martelli MF
    Thymus; 1983 Sep; 5(5-6):429-32. PubMed ID: 6362105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of cell-mediated immunity to staging, histology and prognosis in untreated patients with Hodgkin's disease.
    De Gast GC; Halie MR
    Neth J Med; 1976; 19(4-5):196-200. PubMed ID: 980187
    [No Abstract]   [Full Text] [Related]  

  • 16. Studies of cell subpopulations mediating mitogen hyporesponsiveness in patients with Hodgkin's disease.
    Sibbitt WL; Bankhurst AD; Williams RC
    J Clin Invest; 1978 Jan; 61(1):55-63. PubMed ID: 304068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune condition in patients with Hodgkin's disease.
    Zywicka-Lopaciuk H; Konopka L; Traczyk Z; Pawelski S; Sylwestrowicz T; Maślanka K; Arczyńska-Brojer E; Cieśluk S; Karpowicz M; Małkowska-Zwierz W
    Arch Immunol Ther Exp (Warsz); 1980; 28(1):153-60. PubMed ID: 6968189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro lymphocyte response to the phytomitogens in untreated and treated patients with Hodgkin's disease.
    Romagnani S; Amadori A; Biti G; Bellesi G; Ricci M
    Int Arch Allergy Appl Immunol; 1976; 51(3):378-89. PubMed ID: 1279027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of levamisole on cell-mediated immune responses in patients with nasopharyngeal carcinoma.
    Goh EH; Chan SH; Simons MJ
    IARC Sci Publ (1971); 1978; (20):503-10. PubMed ID: 730200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Defect in lectin-induced interleukin 2 (IL-2) production by peripheral blood lymphocytes of patients with Hodgkin's disease.
    Soulillou JP; Douillard JY; Vie H; Harousseau JL; Guenel J; le Mevel-le Pourhiet A; le Mevel B
    Eur J Cancer Clin Oncol; 1985 Aug; 21(8):935-9. PubMed ID: 3876220
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.